Delivering on HopeTM

NBI-1065845

NBI-1065845 (TAK-653) is being developed by Neurocrine Biosciences, Inc. and Takeda Pharmaceutical Company Limited as part of a strategic collaboration announced in June 2020. It is a potential first-in-class Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid (AMPA) potentiator for the treatment of TRD. NBI-1065845 has completed several Phase I studies in healthy participants and preparations are underway for a Phase II study in adult patients.